Defence Online

The current contract for Laboratory services – Framework Lead is projected to end on 14-JAN-19 and may be available for retender. Manufacture of a Ricin Antitoxin.
Laboratory services. Research laboratory services. Research and development services and related consultancy services. Research and Development services on security and defence materials. Medical equipments, pharmaceuticals and personal care products. Pharmaceutical products. Pharmaceutical articles. The Authority has a requirement for a ricin antitoxin medicinal product that is licenced for adult human use. The product is intended for use as a lifesaving treatment following ricin toxin poisoning and in particular from exposure to the toxin by the inhalation route. The Authority is seeking a Contractor to produce de-speciated F(ab’)2 anti-ricin antibodies as a lyophilised product. These antibodies are to be generated in a mammalian species and must be capable of neutralising ricin toxin activity following reconstitution. The therapeutic antibody Drug Product F(ab’)2 is to be stable for a minimum of 3 years when stored at 5°C. The Contractor must be able to demonstrate compliance with current Good Manufacturing Practice (cGMP).
Common procurement vocabulary (CPV): 71900000, 73111000, 73000000, 73400000, 33000000, 33600000, 33680000,